🔗 Share this article

As the US proceeds with unprecedented revisions to its vaccination guidelines, an unexpected name has emerged somewhat surprisingly: Tracy Beth Høeg, a US-based physician and public health researcher who rose to prominence by expressing skepticism about Covid shots in the pandemic and has focused upon possible fatalities after Covid vaccination in her short position at the Food and Drug Administration.

Planned Overhauls to Pediatric Vaccine Program

Health officials had intended to announce radical revisions to the childhood vaccination calendar recently, bringing the US with the Danish immunization schedule, sources say – a major change that would put the US at odds with much of the global community with insufficient data for benefit. This reveal has been postponed until the new year.

Instead of Vinay Prasad, Tracy Beth Høeg is scheduled to address the audience at the event. She was recently named temporary leader of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth person to lead the office this year.

A New Direction at the FDA

The acting appointment could signify a closer partnership between the pharmaceutical and biologics divisions as Dr. Høeg and Dr. Prasad solidify control at the FDA – and it signals a renewed priority upon rolling back long-standing vaccines at the FDA.

Dr. Høeg has repeatedly called for discontinuing some childhood vaccine recommendations in the US to become more similar to the Danish model, a society with universal health coverage and a citizenry about the population of the state of Wisconsin.

So far statements, she has continued to focus on vaccines – typically the responsibility of Dr. Prasad, head of the FDA’s Center for Biologics Evaluation and Research (CBER) – instead of medication approval.

Questions Over Expertise

Høeg has no apparent track record in pharmaceutical research, regulation or leadership, which has been typical for past directors of the biologics center. She has served at the FDA as a senior adviser to the agency head and the vaccine center since spring.

“It seems she lacks to have the necessary background” for leading the pharmaceutical oversight division, remarked Jonathan Howard. “She has not conducted a scientific study. She has no expertise in managing a large organization. She has no expertise in industry regulation.”

Past directors of CBER would “be deeply familiar with regulatory frameworks and the underlying principles of pharmaceutical innovation”, noted Janet Woodcock. “Clearly, she doesn’t have the type of experience that former directors who headed the center have had.”

The drug center has an immense range of responsibilities at the agency, the former commissioner pointed out.

“Everybody just zeroes in on the new drug program, but the generic drug division clears numerous generic drugs. There’s a biosimilars program, non-prescription drug unit and more, and every single one have to be managed,” Dr. Woodcock said. “The thing you don’t keep your eye on, that’s the thing that I always told people is going to bite you.”

Additionally, a substantial management component to the job, which oversees over 5,000 staff members. “It is a huge leadership role, if you perform it correctly,” she said.

Response and Controversial Policies

Regarding inquiries about Høeg’s qualifications and whether this appointment represents more teamwork among regulatory chiefs on immunizations, a representative responded that the “inquiries are based on inaccurate assumptions”.

“Her resume is consistent with the duties of her position,” the representative said, noting the time Høeg spent counseling the FDA commissioner on “pharmaceutical safety and approval science, including computerized risk analysis and shot safety tracking”.

As the temporary head, Dr. Høeg assumes responsibility for the commissioner’s recently launched priority voucher program, a disputed one-day medication authorization process that apparently troubled her predecessors. “How are these drugs being chosen for this voucher program? Who is making the calls?” Howard said. “There is a lot of secrecy occurring at the FDA right now.”

Broadly speaking, he said, “the FDA appears to be shifting towards more relaxed regulations of most medications, aside from shots.”

Documented History on Immunizations

Concerning immunizations, Høeg has a more documented, if troubling, past, Howard observe. She released a research paper using unverified volunteer-provided data to estimate the rate of heart inflammation following COVID-19 immunization. She consulted for the Florida chief medical officer Joseph Ladapo, who reportedly have altered data to suggest Covid vaccinations are more dangerous than they are.

Included in her “desired changes” for the current administration encompassed revising regulations for novel immunizations and discontinuing “non-essential” immunizations, she stated following the vote on a podcast. At the agency, Dr. Høeg has allegedly floated the idea of preventing adolescent males from obtaining COVID-19 vaccines.

“She is an all-around ideologue who starts off with her preconceived notions and works backwards to fit the data in a very disingenuous, dishonest fashion,” Howard stated.

Taking Control and a “Campaign of Retribution”

Dr. Høeg joined other contrarians, {like|